NASDAQ
Amneal Pharmaceuticals, Inc. - Class A (AMRX)
♥ 612 Thanks from members
Amneal Pharmaceuticals (AMRX) demonstrates strong financial momentum and upwardly revised 2026 guidance, driven by affordable medicines, specialty segments, and the Kashiv BioSciences biosimilars acquisition, though stretched valuations and execution risks temper enthusiasm.